Storia in 3 fonti

Draig nets $65M to advance depression drug aimed at rebuilding synapses

Draig Therapeutics closes an oversubscribed $65M Series B, advancing its depression drug DT-101 through Phase 2 and toward potential Phase 3.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Draig Therapeutics closes an oversubscribed $65M Series B, advancing its depression drug DT-101 through Phase 2 and toward potential Phase 3.

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.